Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum is based in Cambridge, UK and listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
Scendea is an international product development, regulatory and compliance consulting group serving the pharmaceutical and biotechnology industry.
Scendea’s expert team delivers strategic and operational support in the fields of Non-Clinical, CMC, Clinical and Regulatory to successfully guide products from early development to marketing approval.
In addition, our dedicated Compliance division strengthens development programs through CRO & CDMO oversight, GxP audits, Quality Management System (QMS) support, and GxP training, ensuring robust quality frameworks and inspection readiness throughout the product lifecycle.
A combination of scientific excellence, industry experience, commercial awareness and a collaborative approach allows our team to solve complex issues associated with medicinal product development. With team members based in the US, the Netherlands, Australia and the UK, Scendea delivers innovative, high-quality solutions aligned with jurisdiction-specific regulatory requirements.
At Scendea we collaborate, innovate, and together with our clients, we succeed.
Scitribe is a boutique strategic communications consultancy focused on science and technology, including profile-raising, writing and research. It combines professional corporate and scientific communications expertise with lab-based research experience.
Driven by deep understanding and enthusiasm, it applies strategic thinking and listening, combined with a roll-up-your-sleeves & "get it done" know-how, to deliver real value-add output that helps organisations achieve their business and communications objectives.
We apply big-picture thinking and specialist insights to develop strategies that effectively communicate organisations’ impact while ensuring the accurate translation of science for all target audiences and stakeholders. Scitribe provides bespoke, focused and flexible support to provide the clarity, focus, and style that effectively tells our clients’ story through the right channels, to the right audiences.
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
We are Simbec-Orion, who for almost five decades, have been providing clinical trial management services across a wide range of therapeutic indications and phases. The clinical research organisation with a flexible, specialist approach, we strive to become a trusted partner for our clients. Our passion as a CRO is rare diseases and oncology.
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facilities in Nottingham and Alderley Park, UK housing over 500 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.
